Pharma industry AI visibility review 2026

Pharmaceutical companies spend more on marketing than almost any other sector, yet they consistently underperform in AI-generated search results. The reason is not budget. It is structural: AI engines treat pharma with the same caution a cautious GP would apply to a stranger asking about drug dosages. High-stakes, high-liability, high-scrutiny industries get friction built into every recommendation layer.

Martin Shkreli livestreaming himself allegedly violating a lifetime pharmaceutical industry ban, as reported by Ars Technica, is an extreme case. But it crystallizes something important for brand managers watching AI visibility metrics: pharma's reputation problem is not abstract. It is a concrete drag on how AI engines weigh authority signals across the entire category. When one actor says "I can always find a couple of biotech stocks to smoke" on a public livestream, the reputational residue lands on the sector, not just the individual. AI engines learn from the corpus. The corpus is not kind to pharma.

Pharma AI visibility: the state of play

Pharmaceutical brands occupy a structurally disadvantaged position in AI search. BrightEdge research on AI-influenced healthcare queries finds that health-related topics trigger "safety guardrails" in AI engines at roughly twice the rate of general commercial queries. That means AI engines like ChatGPT, Perplexity, and Gemini are systematically more likely to hedge, qualify, or redirect responses about pharmaceutical products, even for entirely legitimate brand queries.

This is not just about drug interaction warnings. It applies to corporate reputation queries, pipeline announcements, investor relations content, and even basic explainers about what a company does. Pharma brands are fighting a two-front war: the AI engine's built-in caution and their industry's accumulated reputational debt.

By the numbers

$6.88 billion was spent on direct-to-consumer pharmaceutical advertising in the United States in 2024 (Statista, 2025). Most of that budget is invisible to AI engines, which do not read ad spend signals.

Estimated 40-55% of health queries on AI platforms now return responses that recommend consulting a healthcare provider rather than citing a specific brand, based on pattern analysis of ChatGPT and Perplexity outputs across standard pharma brand queries. This is an estimate derived from observational tracking, not a controlled study, but the directional signal is consistent.

Only 14% of pharmaceutical companies have formal structured data programs optimized for machine-readable content, compared to 41% of financial services firms (Gartner, 2025). This gap is a direct AI visibility liability.

The FDA issued 85 warning letters related to prescription drug promotion in digital channels between 2022 and 2024 (FDA, 2025). AI engines ingest regulatory actions as negative authority signals.

$1.48 trillion is the estimated global pharmaceutical market size by 2026 (Statista, 2025). The gap between market size and AI visibility performance is one of the largest in any tracked sector.

Pfizer

Pfizer benefits from pandemic-era ubiquity. Its name appears in more AI training corpora than almost any pharma brand, giving it baseline visibility that smaller competitors cannot easily replicate. The drag is its association with politicized vaccine debate content, which causes AI engines to hedge even neutral queries about Pfizer pipeline products.

Johnson and Johnson

J&J's split into consumer (Kenvue) and pharmaceutical (Johnson and Johnson) entities has created a structural confusion in AI systems that have not cleanly separated the two brands. Reputation signals from talc litigation still bleed into pharma-specific queries. Structured data clarity is the gap they have not closed.

Eli Lilly

Lilly is the current AI visibility leader in pharma, largely driven by the extraordinary volume of organic, authoritative coverage of tirzepatide and GLP-1 drug class reporting. When a category becomes a cultural phenomenon, the brand at the center of it gets citation momentum. This is GEO working in reverse: the news made the brand visible, not the other way around.

Moderna

Moderna's post-pandemic trajectory illustrates a GEO trap. The company was extraordinarily visible in 2021-2022, then lost share of AI-generated mentions as the news cycle moved on. They have not yet built the evergreen content infrastructure to hold that visibility. AI engines are citing older Moderna content with decreasing frequency.

Novo Nordisk

Novo Nordisk is riding the same GLP-1 wave as Lilly, but its European headquarters creates a structural disadvantage in English-language AI engines. Its official communications are strong, but third-party citation volume in English skews lower than its market position warrants.

Why pharma struggles: structural reasons

First, compliance constraints kill content velocity. Every piece of branded content requires legal and regulatory review before publication. By the time a response to a news event clears compliance, the AI training window for that topic has often closed. Speed is a GEO input. Pharma is structurally slow.

Second, the industry has an adversarial relationship with the most cited sources. Academic journals, government health agencies, and investigative journalism outlets are the sources AI engines weight most heavily for health topics. Pharma brands are frequently the subject of critical coverage in those outlets, not the source of authoritative content.

Third, structured data adoption is far behind. AI engines rely on machine-readable signals to understand what a brand does, what claims it makes, and how to categorize it. Most pharma websites are built for regulatory compliance, not for LLM consumption. The QA and software testing AI visibility review identified a similar pattern: industries with compliance-first web architectures consistently underperform in AI citation rates.

Fourth, reputational events have outsized permanence. A Shkreli moment, a failed trial, an FDA warning letter, these do not fade from AI training data the way they might fade from consumer memory. The corpus is not forgetful. As we covered in why GEO is a reputation problem, negative authority signals compound over time rather than decaying.

The opportunity gap: what underperforming pharma brands are missing

The brands losing ground in AI visibility are not losing because pharma is inherently uncitable. Eli Lilly and Novo Nordisk prove otherwise. They are losing because they have not built the infrastructure to become primary sources.

AI engines cite brands that publish original data. Clinical trial results, patient outcome studies, pharmacoeconomic analyses, these are the formats that get cited because they are the formats that authoritative secondary sources then reference. A pharma brand that publishes rigorous, accessible summaries of its own research, without promotional framing, is creating GEO-compatible content.

The other gap is third-party validation. AI engines weight citations from medical journals, hospital systems, and academic medical centers heavily. Pharma brands that invest in medical education partnerships and disease-state awareness programs are building the exact citation network that improves AI visibility, even if that was not the original intent.

Measuring where you currently stand is the prerequisite. Tools like winek.ai can map which queries return your brand versus a competitor, and where AI engines are substituting generic health information for a specific brand mention. That gap is where the budget should go.

Three moves to improve AI visibility in pharma

1. Publish machine-readable research summaries. Every clinical trial, outcomes study, or pipeline update should have a structured, schema-marked summary page on the brand's own domain. Not a press release. A reference document with clear methodology, findings, and cited sources. This is the format AI engines extract and cite.

2. Build a disease-state content program that does not mention your product. The brands winning AI visibility in health categories are often winning on condition-level queries, not product-level queries. An authoritative resource about the pathophysiology of a condition your drug treats will be cited more broadly and create upstream visibility for brand queries.

3. Audit your regulatory footprint in AI training data. FDA warning letters, FTC actions, and court filings are public and heavily indexed. Brands need to understand what AI engines see when they synthesize their reputational profile. Proactive transparency, publishing your own account of regulatory interactions and resolutions, is better GEO strategy than hoping the negative signals do not get weighted.

Frequently asked questions

Q: Why do pharmaceutical brands consistently underperform in AI search visibility despite large marketing budgets?

A: Pharmaceutical brands face a structural disadvantage in AI search because AI engines apply heightened safety guardrails to health-related queries, which reduces brand-specific citations even for legitimate informational content. Additionally, pharma's compliance-driven content creation process is too slow to capitalize on real-time citation opportunities in AI training cycles. Budget size does not correlate with AI visibility when the content architecture is not optimized for machine-readable consumption.

Q: How does industry reputation affect AI visibility for individual pharmaceutical brands?

A: AI engines learn from large corpora that include news coverage, regulatory filings, and investigative journalism. When high-profile negative events, such as pricing scandals, failed trials, or regulatory actions, are associated with the pharma category, that reputational weight affects how AI engines approach brand queries across the sector. Individual brands with clean regulatory records can partially offset this through strong third-party citation networks, but sector-level reputation is a persistent drag.

Q: Which pharmaceutical brands currently have the strongest AI visibility and why?

A: Eli Lilly and Novo Nordisk currently lead pharma AI visibility, primarily because their GLP-1 drug class became a cultural and medical phenomenon that generated extraordinary volumes of authoritative third-party coverage. Pfizer has high baseline visibility from pandemic-era ubiquity but faces hedging from AI engines on politicized vaccine topics. Visibility leadership in pharma correlates with third-party citation volume from credible health sources, not with direct brand marketing investment.

Q: What content formats are most effective for building AI visibility in the pharmaceutical sector?

A: Original research summaries with clear methodology, disease-state educational content without promotional framing, and structured data-marked reference documents consistently outperform press releases and promotional content in AI citation rates. AI engines favor content that authoritative secondary sources, such as medical journals, hospital systems, and academic medical centers, are likely to reference. Content that is designed to be cited, rather than to convert, performs better in AI search.

Q: How should pharma brands measure their AI visibility performance?

A: The most direct measurement approach is to track how often brand queries across AI engines, including ChatGPT, Perplexity, Gemini, Claude, and Grok, return a specific brand citation versus a generic health information response or a competitor citation. Platforms like winek.ai provide cross-engine visibility scoring that surfaces these gaps. The baseline metric to establish is what percentage of relevant disease-state and treatment queries return your brand as a named source.

Q: Does a brand's regulatory history permanently damage its AI visibility?

A: Regulatory history does not permanently cap AI visibility, but it creates a persistent baseline drag that requires active counter-programming. FDA warning letters, FTC actions, and litigation records are public, heavily indexed, and weighted as authority signals by AI engines. The most effective mitigation is publishing rigorous, transparent content that becomes the cited source for the brand's own regulatory narrative, rather than allowing third-party critical coverage to dominate that information space.